•  
  •  
 

Bulletin of Chinese Academy of Sciences (Chinese Version)

Keywords

artificial intelligence, biopharmaceutical, paradigm transformation, multimodal models, collaborative innovation ecosystem

Abstract

The biopharmaceutical industry is a critical domain underpinning national scientific and technological innovation development and public health. With the rapid advancement of artificial intelligence (AI) and its deep integration with the life sciences, biomedicine research is undergoing a paradigm shift from traditional experience-driven trial-and-error approaches to data-driven and predictive validation-based models. This study systematically examines the pathways for reshaping research in biomedicine paradigms under the convergence of data-driven, mechanism-driven, and intelligence-driven approaches. It focuses on recent advances in the application of AI across key stages, including drug discovery and design, druggability evaluation, delivery system design and optimization, nonclinical and clinical research, and intelligent manufacturing. Building on these analyses, the study further explores future development trends, highlighting that the integration of multimodal intelligence with mechanistic interpretability, as well as the construction of data-centric collaborative innovation ecosystems, will serve as key drivers for the high-quality development of the AI-enabled biopharmaceutical industry.

First page

1139

Last Page

1151

Language

Chinese

Publisher

Bulletin of Chinese Academy of Sciences

References

[1] Ren F, Aliper A, Chen J, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology, 2025, 43(1): 63-75.

[2] 余江, 张越, 周易. 人工智能驱动的科研新范式及学科应用研究. 中国科学院院刊, 2025, 40(2): 362-370. Yu J, Zhang Y, Zhou Y. A new scientific research paradigm driven by AI and its applications in academic disciplines. Bulletin of Chinese Academy of Sciences, 2025, 40(2): 362-370. (in Chinese)

[3] Gottweis J, Weng W H, Daryin A, et al. Towards an AI co-scientist. (2025-02-26)[2026-03-30]. https://arxiv.org/abs/2502.18864.

[4] Zhang K, Yang X, Wang Y F, et al. Artificial intelligence in drug development. Nature Medicine, 2025, 31(1): 45-59.

 [5] Abramson J, Adler J, Dunger J,et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature, 2024, 630: 493-500.

[6] Priessner M, Lewis R J, Lemurell I, et al. Advancing structure elucidation with a flexible multi-spectral AI model. Angewandte Chemie International Edition, 2026, 65(2): e17611.

[7] Zeng J Q, Jia X B. Quantifying compatibility mechanisms in traditional Chinese medicine with interpretable graph neural networks. Journal of Pharmaceutical Analysis, 2025, 15(8): 101342.

[8] Bai C S, Wu L L, Li R J, et al. Machine learning-enabled drug-induced toxicity prediction. Advanced Science, 2025, 12(16): e2413405.

[9] Mehta K, Maass C, Cucurull-Sanchez L, et al. Modernizing preclinical drug development: The role of new approach methodologies. ACS Pharmacology & Translational Science, 2025, 8(6): 1513-1525.

[10] Yang X D, Liu G L, Feng G H, et al. GeneCompass: Deciphering universal gene regulatory mechanisms with a knowledge-informed cross-species foundation model. Cell Research, 2024, 34(12): 830-845.

[11] Aljovic A, Zhao S Q, Chahin M, et al. A deep learning-based toolbox for Automated Limb Motion Analysis(ALMA) in murine models of neurological disorders. Communications Biology, 2022, 5: 131.

[12] Zehra, Bakhtiyar A, Islam A, et al. AI-driven approaches in therapeutic interventions: Transforming RNA-seq analysis into biomarker discovery and drug development. Drug Discovery Today, 2025, 30(7): 104391.

[13] Sun Q, Wang H P, Xie J, et al. Computer-aided drug discovery for undruggable targets. Chemical Reviews, 2025, 125(13): 6309-6365.

[14] Talkington A M, Cao Y G, Kearsley A J, et al. Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling. Advanced Drug Delivery Reviews, 2025, 227: 115716.

[15] Göller A H, Kuhnke L, Montanari F, et al. Bayer’s in silico ADMET platform: A journey of machine learning over the past two decades. Drug Discovery Today, 2020, 25(9): 1702-1709.

[16] Kim S R, Min E K, Lee C M, et al. A biomarker-driven ovary-endometrium organ-on-a-chip mimicking 3D multicellular complexity and menstrual cyclicity for predicting reproductive toxicity. Advanced Science, 2026, 13(30): e11098.

[17] 徐萍, 许丽, 杨若南, 等. 新药研发发展态势分析. 中国科学院院刊, 2024, 39(5): 821-831. Xu P, Xu L, Yang R N, et al. Analysis of research and development trends of new drugs. Bulletin of Chinese Academy of Sciences, 2024, 39(5): 821-831. (in Chinese)

[18] Badani A, de Moraes F Y, Vollmuth P,et al. AI and innovation in clinical trials. npj Digital Medicine, 2025, 8: 683.

[19] Hutson M. How AI is being used to accelerate clinical trials. Nature, 2024, 627: S2-S5.

[20] Teodoro D, Naderi N, Yazdani A, et al. A scoping review of artificial intelligence applications in clinical trial risk assessment. npj Digital Medicine, 2025, 8: 486.

[21] Kirlikovali K O, Chen Z J, Islamoglu T, et al. Zirconium-based metal–organic frameworks for the catalytic hydrolysis of organophosphorus nerve agents. ACS Applied Materials & Interfaces, 2020, 12(13): 14702-14720.

[22] Cheng L, Tan Z Z, Jia Z B, et al. Heuristic data-driven approach for synergistic cobalt (IV)-enamine catalysis. Nature Synthesis, 2026, 5(3): 455-465.

[23] Sondell M, Andersson N, Nilsson B. Automatic generation of a digital twin for continuous antibody capture. Journal of Chromatography A, 2026, 1766: 466611.

[24] Zhu Q Q, Dong P J, Yu J Y, et al. COFcap2, a recyclable tandem catalysis reactor for nitrogen fixation and conversion to chiral amines. Nature Communications, 2025, 16: 992.

[25] Zhang C W, Yang L X, Qin Y J, et al. An AI-native biofoundry for autonomous enzyme engineering: Integrating active learning with automated experimentation. (2026-02-01)[2026-06-17]. https://www.biorxiv.org/content/10.64898/2026.02.01.703093v1.

[26] Chen X Z, Wang A, Yin S, et al. Agentic AI for self-driving laboratories in soft matter: Taxonomy, benchmarks, and open challenges. (2026-01-25)[2026-06-17]. https://arxiv.org/abs/2601.17920.

[27] Wang B C, Zhang J. AI-SLMS: An AI-integrated framework for predictive maintenance, intelligent scheduling, and access control in university laboratory management systems. Informatica, 2026, 50(5): 357-374. *Corresponding author

[28] Xu S T, Huang Y T, Shen X, et al. Innovating cell culture process development with deep learning-powered robotic experimentation using the first Industrial Smart Lab Framework. Biotechnology Progress, 2025, 41(6): e70051.

[29] Hao M S, Gong J, Zeng X, et al. Large-scale foundation model on single-cell transcriptomics. Nature Methods, 2024, 21(8): 1481-1491.

[30] Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead.Nature Machine Intelligence, 2019, 1(5): 206-215.

[31] Wilkinson M D, Dumontier M, Aalbersberg I J, et al. The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 2016, 3: 160018.

Download
Request a Copy

Share

COinS